Cabozantinib, Free Base

Hazard statements (CLP)

H302+H312+H332

Code

Statements

H302+H312+H332

Harmful if swallowed, in contact with skin or if inhaled

Hazard statements

pharmaceutically active substance May be harmful if swallowed, inhaled, or absorbed through the skin Ingestion may result in diarrhea, stomatitis (inflammation and ulcer formation in the mouth), palmar-plantar erythrodysesthesia syndrome (also known as hand-foot syndrome manifested as redness, tenderness, peeling, blistering and ulceration of the palms and soles), anorexia (decreased appetite), weight loss, vomiting, asthenia (lack of muscle strength), nausea, fatigue, oral pain, hair color changes, dysgeusia (distortion of the sense of taste), hypertension (elevated blood pressure), abdominal pain, constipation, elevated liver enzymes (ALT/AST/ALP), lymphopenia/neutropenia (reduced levels of different types of white blood cells), thrombocytopenia (reduced blood platelets), hypocalcemia (low serum calcium levels), hypophosphatemia (reduced serum phosphate level), hyperbilirubinemia (increased levels of bilirubin in the blood), pancreatitis/elevated levels of serum lipase, hemorrhage, pneumonia, septicemia, fistulas (abnormal connection between two parts of the body), cardiac arrest, and respiratory failure Exposure may cause irritation of the skin, eyes, mucous membranes, and upper respiratory tract H302+312+332 - Harmful if swallowed, in contact with skin or if inhaled

Precautionary statements

P2562 - Do not get in eyes, on skin or on clothing WARNING For Laboratory Research Use Only